Filings
| Filing | Date | Type | Filed with |
|---|
| Notification of cessation of securities - CHM | Oct 30, 2026 | Financing | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 29, 2026 | Meeting notice | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 29, 2026 | Quarterly report | ASX |
|---|
| Ceasing to be a substantial holder for CHM | Oct 8, 2026 | Ownership change notice | ASX |
|---|
| Notice of initial substantial holder for CHM | Oct 6, 2026 | Ownership change notice | ASX |
|---|
| Final Director's Interest Notice - LR | Oct 5, 2026 | List of directors | ASX |
|---|
| Final Director's Interest Notice - BG | Oct 5, 2026 | List of directors | ASX |
|---|
| Initial Director's Interest Notice - RM | Oct 5, 2026 | List of directors | ASX |
|---|
| FY2026 Annual Report, creditor update and Board changes | Sep 30, 2026 | Annual report | ASX |
|---|
| Application for quotation of securities - CHM | Sep 29, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - CHM | Sep 21, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - CHM | Sep 3, 2026 | Financing | ASX |
|---|
| Appendix 4E and Preliminary Final Report | Aug 31, 2026 | Results | ASX |
|---|
| Application for quotation of securities - CHM | Aug 27, 2026 | Financing | ASX |
|---|
| Application for quotation of securities - CHM | Aug 20, 2026 | Financing | ASX |
|---|
| CHM ceases enrolment in Phase 1 trial and Company update | Aug 18, 2026 | Operations update | ASX |
|---|
| Trading Halt | Aug 16, 2026 | Trading halt or suspension | ASX |
|---|
| Application for quotation of securities - CHM | Aug 6, 2026 | Financing | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jul 31, 2026 | Quarterly report | ASX |
|---|
| Chimeric receives $1.62M advance on FY26 R&D tax incentive | Jul 29, 2026 | Financing | ASX |
|---|
| Investor Presentation | Jul 27, 2026 | Other filings | ASX |
|---|
| CHM CDH17 Phase 1 clinical trial update - New DL 3 data | Jul 15, 2026 | Operations update | ASX |
|---|
| Appointment of Financial Adviser for Strategic Review | Jun 30, 2026 | Other filings | ASX |
|---|
| CHM announces positive Phase 1/2 data at ASCO | May 31, 2026 | Other filings | ASX |
|---|
| Consolidation/Split - CHM | Mar 18, 2026 | Other filings | ASX |
|---|
| Chimeric receives $1.8 M advance on FY26 R&D tax incentive | Mar 1, 2026 | Financing | ASX |
|---|
| Half Year Report and Appendix 4D 31 December 2025 | Feb 27, 2026 | Interim report | ASX |
|---|
| Portfolio streamlined - return of CHM CLTX to City of Hope | Feb 26, 2026 | Operations update | ASX |
|---|
| Funding and EGM update | Feb 24, 2026 | Financing | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jan 27, 2026 | Quarterly report | ASX |
|---|
| $8.4 M funding to drive CHM CDH17 and resignation of CMO | Dec 22, 2025 | Financing | ASX |
|---|
| Trading Halt | Dec 18, 2025 | Trading halt or suspension | ASX |
|---|
| CDH17 granted FDA Orphan Drug Designation for Gastric Cancer | Dec 7, 2025 | Operations update | ASX |
|---|
| CHIMERIC RECEIVES $4.5M R&D TAX INCENTIVE | Nov 23, 2025 | Financing | ASX |
|---|
| 75% disease control observed in CHM CDH17 trial | Nov 12, 2025 | Other filings | ASX |
|---|
| CHM CORE NK Combination Phase 1b trial update | Nov 12, 2025 | Operations update | ASX |
|---|
| Pause in Trading | Nov 12, 2025 | Trading halt or suspension | ASX |
|---|
| Response to ASX Query Letter | Nov 6, 2025 | Explanation request | ASX |
|---|
| Additional complete responses in CHM CORE-NK Phase 1b trial | Oct 2, 2025 | Other filings | ASX |
|---|
| Disease control and tumour shrinkage observed in CHM CDH17 | Sep 28, 2025 | Operations update | ASX |
|---|
| Appendix 4E and Annual Report | Aug 29, 2025 | Annual report | ASX |
|---|
| CHM CDH17 Clinical Trial Update | Aug 3, 2025 | Operations update | ASX |
|---|
| Chimeric receives $2.5 M advance on FY25 R&D tax incentive | Jun 10, 2025 | Other filings | ASX |
|---|
| CHM CDH17 receives FDA Fast Track | Jun 4, 2025 | Operations update | ASX |
|---|
| CHM CDH17 ADVANCES TO DOSE LEVEL 2 | May 20, 2025 | Operations update | ASX |
|---|
| $6.6 million Placement to advance clinical trial pipeline | May 20, 2025 | Financing | ASX |
|---|
| ADVENT-AML Phase 1B clinical trial update | May 15, 2025 | Other filings | ASX |
|---|
| Completion of Entitlement Offer | Apr 24, 2025 | Financing | ASX |
|---|
| Prospectus | Mar 17, 2025 | Offer document | ASX |
|---|
| Entitlement Offer to raise approximately $3.2 million | Mar 17, 2025 | Financing | ASX |
|---|
| Reinstatement to Quotation | Mar 4, 2025 | Trading halt or suspension | ASX |
|---|
| Chimeric announces intention to undertake Entitlement Offer | Mar 4, 2025 | Financing | ASX |
|---|
| Suspension from Quotation | Mar 2, 2025 | Trading halt or suspension | ASX |
|---|
| Half Year Report and Appendix 4D 31 December 2024 | Feb 28, 2025 | Interim report | ASX |
|---|
| $4.0m Non-Dilutionary Funding | Feb 27, 2025 | Other filings | ASX |
|---|
| Phase 1B CHM CORE-NK trial advances to newly diagnosed AML | Dec 15, 2024 | Operations update | ASX |
|---|
| Chimeric receives $4.17m R&D tax incentive | Nov 27, 2024 | Results | ASX |
|---|
| AGM Presentation and CEO Appointment | Nov 11, 2024 | Meeting outcome | ASX |
|---|
| Reinstatement to Official Quotation | Oct 21, 2024 | Trading halt or suspension | ASX |
|---|
| $5 million Placement to progress CHM CDH17 trial | Oct 21, 2024 | Financing | ASX |
|---|
| AML patient achieves Complete Response in CHM CORE-NK trial | Oct 6, 2024 | Operations update | ASX |
|---|
| Appendix 4E and Preliminary Final Report | Aug 30, 2024 | Results | ASX |
|---|
| First patient dosed in Phase 1/2 trial of CHM CDH17 | Aug 28, 2024 | Other filings | ASX |
|---|
| First patient enrolled in CHM CDH17 Phase 1/2 clinical trial | Jul 22, 2024 | Operations update | ASX |
|---|
| Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA | Jun 4, 2024 | Operations update | ASX |
|---|
| Chimeric opens CHM CDH17 Phase 1/2 trial | May 22, 2024 | Operations update | ASX |
|---|
| CHM CDH17 Phase 1/2 clinical trial approved for initiation | May 19, 2024 | Operations update | ASX |
|---|
| Resignation of CEO and Managing Director | May 1, 2024 | Management or board change | ASX |
|---|
| Clinical milestones for 2024 & 2023 successes highlighted | Mar 13, 2024 | Operations update | ASX |
|---|
| Half Yearly Report and Accounts | Feb 28, 2024 | Interim report | ASX |
|---|
| 1st patient treated in ADVENT-AML Phase 1b clinical trial | Feb 7, 2024 | Other filings | ASX |
|---|
| Placement of Entitlement Offer Shortfall | Jan 18, 2024 | Financing | ASX |
|---|
| ADVENT-AML Phase 1B clinical trial open to enrolment | Jan 14, 2024 | Operations update | ASX |
|---|
| CHIMERIC RECEIVES $7.36M R&D TAX INCENTIVE | Jan 9, 2024 | Financing | ASX |
|---|
| Positive in vitro data for CHM 1301 CAR NK cells | Nov 22, 2023 | Other filings | ASX |
|---|
| 1st patient dosed in Phase 1b recurrent glioblastoma trial | Nov 1, 2023 | Operations update | ASX |
|---|
| FDA clearance of IND for CHM 2101 | Oct 30, 2023 | Other filings | ASX |
|---|
| Entitlement Offer to raise approximately $10 million | Oct 24, 2023 | Financing | ASX |
|---|
| New data for Phase 1A CLTX CAR T brain cancer clinical trial | Oct 22, 2023 | Other filings | ASX |
|---|
| Agreement with MD Anderson for Phase 1B CHM 0201 AML study | Sep 12, 2023 | Other filings | ASX |
|---|
| Dosing completion in Phase 1A brain cancer clinical trial | Aug 28, 2023 | Other filings | ASX |
|---|
| Chimeric to receive A$4.4 million introduction fee | Aug 16, 2023 | Other filings | ASX |
|---|
| Positive data - CHM 0301 next-gen armoured NK cell platform | Aug 14, 2023 | Other filings | ASX |
|---|
| CHM secures up to A$12.6m through SPP and placements | Jun 23, 2023 | Financing | ASX |
|---|
| Share purchase plan completed | Jun 23, 2023 | Financing | ASX |
|---|
| Launch of new Phase 1B Glioblastoma clinical trial | Jun 4, 2023 | Other filings | ASX |
|---|
| SPP offer documents issued to shareholders | May 22, 2023 | Offer document | ASX |
|---|
| BOARD & MANAGEMENT COMMIT TO $1M PLACEMENT AND PROPOSED SPP | May 15, 2023 | Financing | ASX |
|---|
| New CLTX CAR technology patent protection in India & Israel | Apr 28, 2023 | Other filings | ASX |
|---|
| Phase 1B brain cancer clinical trial approved for initiation | Apr 25, 2023 | Other filings | ASX |
|---|
| CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation | Apr 3, 2023 | Other filings | ASX |
|---|
| Positive pre-IND meeting with FDA for Phase 1 CAR T study | Mar 20, 2023 | Other filings | ASX |
|---|
| Fourth dose cohort initiated in CHM 1101 Phase 1 trial | Mar 2, 2023 | Other filings | ASX |
|---|
| Appendix 4D and Half Year Report | Feb 28, 2023 | Interim report | ASX |
|---|
| CHIMERIC RECEIVES $3.06M R&D TAX INCENTIVE | Feb 14, 2023 | Other filings | ASX |
|---|
| Follow up period completed for 3rd cohort in CHM 1101 trial | Jan 22, 2023 | Other filings | ASX |
|---|
| Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trial | Dec 21, 2022 | Other filings | ASX |
|---|
| Exclusive license agreement with CWRU for CORE-NK platform | Nov 20, 2022 | Other filings | ASX |
|---|
| Patent received in Japan for CLTX CAR technology | Aug 2, 2022 | Other filings | ASX |
|---|
| Licenses viral vector technology from Penn for CDH17 | Jun 28, 2022 | Other filings | ASX |
|---|
| A$30 million Equity Placement Agreement with L1 Capital | Jun 9, 2022 | Financing | ASX |
|---|
| Strategic manufacturing partnership with WuXi ATU | Apr 12, 2022 | Other filings | ASX |
|---|
| Security Class Reinstatement to Quotation CHMO | Mar 27, 2022 | Trading halt or suspension | ASX |
|---|
| CDH17 CAR T PRECLINICAL DATA FEATURED IN NATURE CANCER | Mar 23, 2022 | Other filings | ASX |
|---|
| Completion of retail component of Entitlement Offer | Mar 22, 2022 | Financing | ASX |
|---|
| Security Class Suspension from Quotation CHMO | Mar 20, 2022 | Trading halt or suspension | ASX |
|---|
| Final Results in Phase 1 Trial of CORE NK Platform | Mar 6, 2022 | Other filings | ASX |
|---|
| CHIMERIC PARTNERS WITH BE THE MATCH BIOTHERAPIES | Mar 4, 2022 | Other filings | ASX |
|---|
| Successful completion of Institutional Entitlement Offer | Feb 22, 2022 | Financing | ASX |
|---|
| Entitlement Offer to raise approximately $18.1 million | Feb 21, 2022 | Financing | ASX |
|---|
| Encouraging data from 2nd dose cohort in CLTX CAR T trial | Feb 7, 2022 | Other filings | ASX |
|---|
| Sponsored Research Agreement with University of Pennsylvania | Jan 31, 2022 | Other filings | ASX |
|---|
| Chimeric receives US patent covering CLTX CAR technology | Jan 26, 2022 | Other filings | ASX |
|---|
| Transformative Portfolio Expansion Presentation | Nov 30, 2021 | Other filings | ASX |
|---|
| CLTX CAR T data shows regional control of tumour recurrence | Nov 21, 2021 | Other filings | ASX |
|---|
| CLTX CAR T PRESENTS POSITIVE INITIAL PHASE 1 CLINICAL DATA | Nov 14, 2021 | Other filings | ASX |
|---|
| FIRST MILESTONE ON PATH TO CDH17 CAR T CLINICAL TRIAL | Oct 21, 2021 | Other filings | ASX |
|---|
| European patent granted for CLTX technology used in CHM 1101 | Sep 23, 2021 | Other filings | ASX |
|---|
| Partnership with OncoBay Clinical to advance CHM 1101 | Sep 2, 2021 | Other filings | ASX |
|---|
| Preliminary Final Report | Aug 31, 2021 | Results | ASX |
|---|
| Chimeric Appoints Jennifer Chow as CEO & MD | Aug 30, 2021 | Other filings | ASX |
|---|
| IND clearance received from US FDA for CHM 1101 | Aug 19, 2021 | Other filings | ASX |
|---|
| Chimeric licenses novel solid tumor CAR T therapy from Penn | Jul 27, 2021 | Other filings | ASX |
|---|
| Second Dose Cohort Initiated in CLTX CAR T Phase 1 Trial | May 23, 2021 | Other filings | ASX |
|---|
| Appendix 4C - quarterly | Apr 23, 2021 | Quarterly report | ASX |
|---|
| Successful Completion of First Patient Cohort Phase 1 Trial | Apr 21, 2021 | Other filings | ASX |
|---|
| Successful Completion of Dosing in First Patient Cohort | Mar 17, 2021 | Other filings | ASX |
|---|